Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 in Neurological Autoimmune Diseases
NCT07337785Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in multiple sclerosis (MS), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and 1 more, sponsored by Tongji Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 24 months, Serious Adverse Events at 24 months and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
RD06-05
03
Conditions
multiple sclerosis (MS)myasthenia gravis (MG)chronic inflammatory demyelinating polyneuropathy (CIDP)Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT07337785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337785.